Shanghai De Novo Pharmatech announced achievement of important First-in-Human milestone in the US in Phase I Trials with the novel investigational TLR8 agonist DN1508052. The Phase I open-label, multi-center study is designed to investigate the safety, tolerability, pharmacokinetics and preliminary antitumor activity of DN1508052 in US patients with advanced solid tumors and to determine the recommended Phase II dose in these patients (  identifier NCT03934359).